Pre-made Necitumumab benchmark antibody ( Whole mAb, anti-EGFR therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-371
Anti-EGFR therapeutic antibody (Pre-made Necitumumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR). The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC). It was counterproductive in non-squamous non-small-cell lung carcinoma.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-EGFR therapeutic antibody (Pre-made Necitumumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||6b3s:JK:CD:HL:FG/3b2u:WX:QR:TU:JK:CD:NO:FG:HL/3b2v:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||ImClone Systems;Eli Lilly|
|Conditions Approved||Non-small cell lung cancer|
|Conditions Active||Solid tumours|
|Conditions Discontinued||Colorectal cancer|